Health Canada MDL & MDEL Registration Consultant
MDSAP Canada | Your Partner for Canadian Market Access
End-to-end regulatory, quality and compliance support for Medical Devices, IVDs and Combination Products in Canada.
Health Canada Regulatory Expertise
Deep knowledge of Canada's requirements
MDL & MDEL Registration Support
Complete registration from planning to approval
MDSAP Canada Certification
End-to-end support for single audit program
Post-Market Compliance
Vigilance, reporting & PMS support
Local Presence in Canada
Canadian regulatory and quality experts
End-to-End Support
From strategy to ongoing compliance
Our Health Canada Regulatory Services
1. Regulatory Strategy & Product Classification
- •Classify your device under MDR SOR/98-282
- •Define licensing pathway (MDL, MDEL, IVD)
- •Identify applicable standards & labelling requirements
2. MDL & MDEL Registration
- •MDL (Medical Device Licence) applications
- •MDEL (Medical Device Establishment Licence)
- •Evidence summary, forms & cover letters
3. MDSAP Canada Certification
- •Gap assessment to MDSAP (SOR/98-282 & ISO 13485)
- •Audit readiness & CAPA support
- •Coordination with MDSAP CABs
4. Technical Documentation Review
- •Review of Essential Principles compliance
- •Risk management (ISO 14971)
- •V&V, clinical/performance evidence, labelling
5. Testing Strategy & Lab Coordination
- •Test plan development
- •Lab selection & coordination
- •Protocol review & worst-case justification
6. Labelling & Bilingual Requirements
- •English & French labelling review
- •Symbols, UDI, IFU & packaging compliance
- •Label change filing support
7. Post-Market Surveillance & Vigilance
- •PMS plan development
- •Adverse event reporting (SOR 98-282 Part 1, Div. 2)
- •Trend analysis & CAPA support
8. Licence Maintenance & Changes
- •Licence renewals
- •Site/address/ownership changes
- •Class changes & scope expansions
9. Manufacturer & Importer Obligations
- •Canadian importer obligations
- •Quality management responsibilities
- •Record retention & traceability
10. IVD Registration Support
- •IVD classification & licensing
- •Analytical & clinical performance evidence
- •Assay validation & labelling
11. Software & Cybersecurity Compliance
- •SaMD classification
- •IEC 62304 & cybersecurity risk management
- •Software change & validation support
12. Compliance Audits & Inspection Support
- •Health Canada inspection readiness
- •Mock audits & compliance assessments
- •Response to findings support
Our End-to-End Canada Regulatory Process
Strategy & Classification
Data & Documentation Preparation
MDL / MDEL Submission
Health Canada Review
Licence Issuance & Maintenance
Post-Market Compliance
Why Choose NKB Regovanta for Canada?
Health Canada Licensing Pathways
Medical Devices (MDL)
Required for Class II, III & IV devices. Sold, leased, advertised or imported into Canada. Licence issued to the device (brand/model).
Establishment Licence (MDEL)
Required for manufacturers, sterilizers, packagers, importers & exporters. Demonstrates compliance with Quality Management System requirements.
In Vitro Diagnostics (IVD)
IVD licensing pathway based on risk classification. Includes assay validation, performance evidence & labelling.
Devices Classes in Canada (SOR/98-282)
MDSAP – Single Audit Program
Canada is a participating country in MDSAP. A single MDSAP audit can satisfy the QMS requirements for Canada along with other MDSAP countries.
Regulations
- • Medical Devices Regulations (SOR/98-282)
- • Food and Drugs Act
- • Guidance & Policies
Standards
- • ISO 13485, ISO 14971
- • IEC 62304, IEC 62366-1
- • Risk-based standards
Reporting Timelines
- • Serious adverse reaction: 10 days
- • Death: 10 days
- • Malfunction: 15 days
- • Complaint: 30 days
Marketed Health Products Database (MHPD)
All MDL, MDEL & licensed products are publicly listed in the MHPD.
Understanding the Canadian Medical Device Licensing Framework
Health Canada regulates medical devices under the Food and Drugs Act and the Medical Devices Regulations (SOR/98-282). Devices are classified from Class I to Class IV according to risk. The regulatory route changes substantially with the class of the device and the role of the establishment in the Canadian supply chain.
Lowest-risk devices. A device-specific MDL is generally not required, but establishment licensing (MDEL) applies to manufacturers, importers and distributors.
Manufacturers require a valid Medical Device Licence (MDL) issued to the manufacturer before the device may be imported or sold in Canada.
Operational licence tied to regulated activities such as manufacturing Class I devices, importing or distributing medical devices across all classes.
Manufacturers of Class II, III and IV devices must maintain ISO 13485 certification issued through a recognized MDSAP auditing organization.
Critical Distinction:
MDL and MDEL are not interchangeable. An MDL is a device licence issued to the manufacturer for Class II, III or IV devices. An MDEL is an establishment licence tied to regulated activities such as manufacturing Class I devices, importing or distributing medical devices.
1. Regulatory Strategy & Product Classification
Classification is the first regulatory decision because it determines the licensing route, submission depth, quality-system expectations and the level of evidence Health Canada will review.
How NKB Approaches Classification:
We begin with the device definition and intended use rather than selecting a class based on a superficially similar product. We assess the regulatory characteristics that drive classification and document the rationale so the downstream licensing strategy is built on a defensible basis.
- • Confirm whether the product meets the Canadian definition of a medical device or IVD.
- • Review intended use, indications, target population and user environment.
- • Apply the non-IVD or IVD classification rules under Schedule 1 of the Medical Devices Regulations.
- • Assess invasiveness, duration of contact, active functions, energy transfer, monitoring functions and consequences of device failure for non-IVDs.
- • For IVDs, assess the analyte, intended purpose, testing context, donor/transfusion implications, disease significance and consequences of an incorrect result.
- • Determine Class I, II, III or IV and the resulting MDL/MDEL/MDSAP route.
- • Identify applicable standards, labelling requirements and evidence expectations.
Expert Focus:
The question is not simply “What class is this device?” It is “What regulatory obligations are triggered by this classification, and what evidence will Health Canada expect for this risk profile?”
2. Medical Device Licence (MDL) - Class II, III & IV
A Medical Device Licence is required for Class II, III and IV medical devices before they may be imported or sold in Canada. The licence is issued to the manufacturer and is tied to the licensed device or device family/grouping.
Class II Applications
Generally a more streamlined licence application, but classification, device identifiers, labelling and MDSAP quality-system evidence must still align.
Class III Applications
Requires a more substantive pre-market review and a structured technical evidence package supporting safety and effectiveness.
Class IV Applications
Highest-risk devices require the most comprehensive evidence package, including detailed safety and effectiveness data and clinical evidence.
Our MDL Support Includes:
- • Licence pathway and application-type assessment
- • Device grouping strategy: single device, family, group or group family
- • Manufacturer and device information review
- • MDSAP certificate and scope alignment
- • Health Canada Regulatory Enrolment Process (REP) data preparation
- • Class-specific application forms and supporting documentation
- • IMDRF Table of Contents dossier planning for Class III and IV submissions
- • Health Canada-specific evidence requirements and regional content
- • Application quality review before submission
- • Response strategy for screening deficiencies or requests for additional info
- • Licence issuance review and post-approval maintenance planning
Expert Focus:
A technically strong dossier is not created by filling every available folder. The evidence must be proportionate to the device class, linked to the safety and effectiveness requirements and presented in a way that allows Health Canada to trace the claim to the supporting data.
3. Medical Device Establishment Licence (MDEL)
An MDEL authorizes an establishment to conduct regulated activities involving medical devices in Canada. It commonly applies to Class I manufacturers and to importers and distributors of medical devices across all classes, subject to regulatory exemptions.
MDEL Is an Operational Compliance Licence:
An MDEL is not simply a company registration. The establishment must have procedures and controls capable of supporting the regulated activities listed on the licence.
- • Determine whether the establishment requires an MDEL and which activities must be included
- • Confirm establishment name, address and regulatory activity information
- • Identify device classes and categories handled by the establishment
- • Review procedures for distribution records and traceability
- • Review complaint handling and escalation procedures
- • Review mandatory problem reporting procedures
- • Review recall procedures and responsibilities
- • Review storage, handling and distribution controls where relevant
- • Assess importer/distributor responsibilities for verifying device licensing and labelling
- • Support annual licence review requirements and licence amendments/notifications
Inspection-Readiness Perspective:
For an MDEL holder, Health Canada may look beyond the existence of procedures and examine whether the establishment can demonstrate effective implementation through records, complaint files, distribution data, recall capability and licensing controls.
4. MDSAP Canada & ISO 13485 Quality-System Readiness
For manufacturers of Class II, III and IV devices, quality-system certification is a core part of the Canadian licensing framework. Health Canada relies on ISO 13485 certification issued through a recognized Medical Device Single Audit Program (MDSAP) auditing organization.
Our MDSAP Support Goes Beyond Certificate Collection:
- • MDSAP gap assessment against ISO 13485 and Health Canada regulatory requirements
- • QMS scope and certificate alignment with the legal manufacturer and licensed devices
- • Design and development controls for applicable device classes
- • Risk-management integration (ISO 14971)
- • Supplier and outsourced-process controls
- • Complaint handling and mandatory reporting
- • Recall and advisory notice processes
- • CAPA and nonconformity controls
- • Change control and licence-impact assessment
- • Post-market surveillance and regulatory reporting interfaces
- • MDSAP audit preparation and response to audit nonconformities
- • Coordination of regulatory evidence with the QMS and technical dossier
Expert Focus:
The MDSAP certificate, the technical dossier and the Health Canada licence should not tell three different stories. The legal manufacturer, device scope, manufacturing controls, design responsibilities and post-market processes must remain aligned.
5. Technical Documentation & Health Canada Evidence Strategy
The level of technical evidence required increases with device risk. For Class III and IV devices, Health Canada uses a structured application framework based on the IMDRF Table of Contents, together with Canada-specific content requirements.
Evidence Architecture We Review:
- • Device description, principles of operation and variants/configurations
- • Intended use, indications, contraindications and target population
- • Device classification and regulatory history
- • Essential principles / Canadian safety and effectiveness requirements
- • Risk-management documentation and benefit-risk reasoning
- • Design verification and validation
- • Bench and functional performance testing
- • Biocompatibility and chemical characterization
- • Sterilization, packaging and shelf-life evidence
- • Electrical safety and EMC where applicable
- • Software verification and validation and cybersecurity where applicable
- • Usability/human factors evidence
- • Clinical evidence for higher-risk devices where required
- • IVD analytical and clinical performance evidence
- • Labelling, IFU and promotional consistency
- • Post-market history and supporting regulatory information
Expert Focus:
We challenge whether each performance claim is actually supported by the evidence submitted, whether the tested configuration represents the marketed device, and whether risk, testing, clinical evidence and labelling remain internally consistent.
6. Testing Strategy & Laboratory Coordination
Testing should be designed around the regulatory question the evidence must answer. NKB Regovanta helps manufacturers define the evidence strategy before studies are initiated and can coordinate testing with established laboratories where external testing is required.
Testing Areas We Can Support:
- • Bench and functional performance testing
- • Biocompatibility and chemical characterization
- • Sterilization validation
- • Packaging and transportation validation
- • Shelf-life and ageing studies
- • Electrical safety and EMC
- • Software verification and validation
- • Cybersecurity testing and documentation
- • Human factors and usability
- • Mechanical and durability testing
- • IVD analytical and clinical performance studies
How NKB Approaches Testing:
- • Define what regulatory question the test must answer
- • Confirm applicable recognized or relevant standards
- • Challenge sample selection and device configuration
- • Identify appropriate worst-case rationale
- • Review comparator/reference method selection
- • Review acceptance criteria before study execution
- • Review protocols for regulatory adequacy
- • Review deviations and impact on interpretability
- • Review reports before dossier integration
- • Trace evidence back to licence application
Our Difference:
We do not simply refer the client to a laboratory. We sit between the manufacturer, laboratory and Health Canada dossier so the generated evidence is fit for regulatory review and does not have to be recreated later.
7. Canadian Labelling, French/English & IFU Compliance
Canadian labelling requirements are not a translation exercise. The label, package, instructions for use and promotional claims must remain consistent with the licensed device, intended use and performance evidence.
Our Labelling Review Includes:
- • Device name and manufacturer identity
- • Device identifier and catalogue/model information
- • Intended use and directions for use
- • Warnings, precautions, contraindications and limitations
- • Sterility, storage and expiry information
- • Primary and secondary packaging
- • IFU and package inserts
- • IVD performance specifications
- • Near-patient IVD labelling considerations
- • Electronic labelling strategy where eligible
- • Alignment of claims with licensed indications and evidence
- • English/French language requirements based on sales channel
Language Requirement:
For devices sold to the general public, specified label information and directions for use must be available in both English and French. For other devices, labelling may be in either official language, with the other official language made available on request. Near-patient IVD requirements should be assessed separately.
8. Health Canada IVD Registration & Performance Evidence
IVDs are classified under a separate Canadian classification framework because risk is driven not only by the assay technology but by how the result will be used and the consequences of an incorrect result.
Our IVD Strategy Includes:
- • IVD qualification and classification
- • Intended-use and specimen-type review
- • Analyte and clinical-use assessment
- • Near-patient / point-of-care considerations
- • MDL pathway for Class II, III or IV IVDs
- • MDSAP and QMS alignment
- • Analytical & clinical performance evidence strategy
- • Reference method/comparator strategy
- • Labelling and performance-claim review
- • Laboratory study coordination
- • IMDRF ToC dossier development
Analytical Performance Studies:
- • Precision, repeatability and reproducibility
- • Analytical sensitivity / limit of detection
- • Analytical specificity
- • Linearity and measuring range
- • Interference and cross-reactivity
- • Cut-off determination where relevant
- • Specimen stability and handling
- • Reagent and calibration considerations
- • Clinical sensitivity and specificity
- • Comparison with reference/comparator method
Expert Focus:
A performance claim should never be stronger than the study design that supports it. We map intended use and performance claims to the analytical and clinical evidence before the dossier is finalized.
9. Medical Device Software, SaMD & Cybersecurity
Software-enabled medical devices and standalone software require a regulatory strategy that connects intended use, classification, software functions, risk controls, verification and validation, cybersecurity and lifecycle change management.
- • Determine whether the software qualifies as a medical device
- • Assess classification under the Canadian framework
- • Define software architecture and system boundaries
- • Review software development lifecycle evidence (IEC 62304)
- • Review software verification and validation
- • Review SOUP / third-party software controls
- • Cybersecurity risk management and threat considerations
- • Interoperability and interface evidence
- • Usability and human factors where relevant
- • Clinical/performance evidence for software-driven claims
- • Predetermined change control strategy for AI/ML functions
- • Post-market monitoring and update controls
Expert Focus:
For software, the licensing question is not only whether the code works. Health Canada must be able to understand what the software does clinically, how failure could affect the user or patient, and how the manufacturer controls changes after licensing.
10. Post-Market Surveillance, Complaints & Mandatory Problem Reporting
Canadian market access continues after licensing. Manufacturers, importers and distributors must maintain complaint, reporting, recall and corrective-action systems capable of identifying and responding to device risks.
Our Post-Market Support Includes:
- • Complaint handling procedures and escalation logic
- • Reportability assessment under the Medical Devices Regulations
- • Preliminary and final incident reporting support
- • 10-day and 30-day mandatory reporting assessment
- • Foreign incident / corrective-action assessment where applicable
- • Trend review and signal assessment
- • Recall strategy and Health Canada communication support
- • Corrective and preventive action (CAPA)
- • Risk-management updates
- • Labelling and IFU updates
- • Licence-impact and change assessment
- • Post-market documentation and regulatory record maintenance
Reporting Logic:
For incidents occurring in Canada, a preliminary report is generally due within 10 calendar days when death or serious deterioration in health has occurred, and within 30 calendar days when such an outcome did not occur but could occur if the incident recurred.
Expert Focus:
We do not treat complaints as isolated quality records. We connect complaint data to reportability, risk, CAPA, recall decisions, licence impact and the technical evidence supporting the device.
11. Licence Amendments, Significant Changes & Lifecycle Maintenance
A Health Canada licence must remain aligned with the device that is actually manufactured and sold. Certain changes to Class II, III and IV devices require a new or amended MDL, while other changes may be documented internally or handled through a different regulatory mechanism.
Changes We Assess:
- • Intended use or indications changes
- • Design and performance changes
- • Material changes
- • Software and cybersecurity changes
- • Manufacturing-site and process changes
- • Supplier changes
- • Sterilization changes
- • Packaging and shelf-life changes
- • Labelling changes
- • Device family/grouping changes
- • Changes to identifiers or model configurations
- • Private label changes
Our Lifecycle Assessment:
- • Determine whether the change affects safety or effectiveness
- • Determine whether the change is significant for MDL purposes
- • Identify required verification/validation
- • Assess whether additional clinical/performance evidence is required
- • Assess impact on risk management and labelling
- • Assess MDSAP/QMS documentation impact
- • Determine whether an amendment or minor-change route is appropriate
- • Update technical dossier and regulatory records
Expert Focus:
The question is not simply “Did the device change?” It is “Does the change alter the basis on which Health Canada accepted the device’s safety, effectiveness, quality or licensed indications?”
12. Manufacturer, Importer & Supply-Chain Compliance
Canadian market access depends on more than the manufacturer’s device licence. The roles of the importer and distributor, MDEL status, traceability, complaint routing and regulatory responsibilities must be clear across the supply chain.
- • Legal manufacturer and establishment-role assessment
- • Importer and distributor MDEL requirements
- • Verification of device licensing before import or sale
- • Distribution records and traceability
- • Complaint communication between Canadian partners and the manufacturer
- • Mandatory reporting responsibilities
- • Recall responsibilities and effectiveness checks
- • Storage, handling and transport controls
- • Regulatory agreements and responsibility mapping
- • Change notification and licence maintenance interfaces
Expert Focus:
A compliant supply chain requires clear ownership of the regulatory decisions: who verifies licence status, who receives complaints, who assesses reportability, who communicates recalls and who maintains the records Health Canada may request.
13. Health Canada Inspection & Compliance Readiness
Health Canada inspections focus on the activities an establishment actually performs. A mature compliance system must demonstrate implementation through records, not only the existence of procedures.
- • MDEL inspection readiness assessment
- • Complaint-file review
- • Distribution-record and traceability review
- • Recall procedure and mock-recall readiness
- • Mandatory problem-reporting controls
- • Labelling and licence verification controls
- • Importer/distributor controls
- • Corrective-action and CAPA evidence
- • Training and responsibility records
- • Response strategy for inspection observations and compliance gaps
Inspection Lens:
Procedure → Record → Regulatory Decision → Evidence of Implementation → Effectiveness
Canadian Device Classes & Market-Access Pathways
| Class | Risk Level | Primary Device Licence Route | Typical Regulatory Depth |
|---|---|---|---|
| Class I | Lowest | No device-specific MDL; MDEL pathway applies based on role | Classification, labelling, establishment controls, post-market obligations |
| Class II | Moderate | MDL | Class II application, MDSAP certificate, labelling, device identifiers, attestation |
| Class III | Higher | MDL with substantive pre-market review | IMDRF ToC dossier, safety/effectiveness evidence, risk, V&V, clinical data |
| Class IV | Highest | MDL with comprehensive pre-market review | Most extensive technical, clinical & risk evidence; high scrutiny of benefit-risk |
Why Manufacturers Choose NKB Regovanta for Canada
- • Regulatory strategy before application preparation
- • Deep understanding of the difference between MDL, MDEL and MDSAP obligations
- • Class-specific evidence strategy rather than one template for every device
- • Technical dossier review from a Health Canada reviewer perspective
- • Testing strategy integrated with the final regulatory submission
- • Coordination with established laboratories for required studies
- • Medical Device and IVD regulatory capability across Classes I to IV
- • Software, cybersecurity and higher-risk technology support
- • Post-market, inspection and lifecycle compliance beyond initial licensing
- • Multi-market perspective that aligns evidence across Canada, US, EU and global frameworks
Our Difference:
We connect Classification → Licence Route → MDSAP → Evidence → Testing → Submission → Health Canada Review → Post-Market Compliance. The objective is not simply to obtain a licence, but to build and maintain a defensible Canadian regulatory position.
Frequently Asked Questions - Health Canada Medical Devices
Key regulatory answers regarding MDL licences, MDEL establishment requirements, MDSAP certification, and bilingual labelling.
What is the difference between an MDL and an MDEL?
An MDL (Medical Device Licence) is a device-specific licence issued to the manufacturer for Class II, III and IV medical devices before they can be sold in Canada. An MDEL (Medical Device Establishment Licence) is an operational licence issued to Class I manufacturers, importers, and distributors authorizing them to import or distribute medical devices in Canada.
Does a Class I medical device require an MDL?
Class I medical devices generally do not require a device-specific Medical Device Licence (MDL). However, the manufacturer, importer or distributor must hold a valid Medical Device Establishment Licence (MDEL) unless a specific regulatory exemption applies.
Is MDSAP certification mandatory in Canada?
Yes. Health Canada requires all manufacturers of Class II, III and IV medical devices to maintain ISO 13485 quality-system certification issued exclusively through a recognized Medical Device Single Audit Program (MDSAP) Auditing Organization.
What information is required for Class III and IV applications?
Higher-risk applications require structured technical evidence supporting safety and effectiveness. Health Canada uses an IMDRF Table of Contents-based structure with Canada-specific content requirements for comprehensive Class III and IV pre-market review (pre-clinical testing, risk management, biocompatibility, software V&V, and clinical evidence).
Can NKB Regovanta coordinate medical device testing?
Yes. Where external studies are needed (biocompatibility, electrical safety, usability, software verification, IVD performance), we help define the test strategy and coordinate with established, accredited laboratories. We also review protocols, worst-case selection, acceptance criteria, and final reports.
Do medical device labels need to be bilingual in Canada?
For devices sold to the general public, specified label information and directions for use must be available in both English and French. For professional-use devices, labelling may be in either official language, with the other official language made available upon request. Near-patient IVD requirements should be assessed separately.
When must an incident be reported to Health Canada under Mandatory Problem Reporting?
For reportable incidents occurring in Canada, a preliminary report is generally required within 10 calendar days when death or a serious deterioration in health has occurred, and within 30 calendar days when such an outcome did not occur but could occur if the incident recurred.
Do changes to a licensed device require an MDL amendment?
Certain changes to Class II, III and IV devices (such as intended use, design, material, software, manufacturing process, or labelling changes) require a significant change amendment application to Health Canada before marketing the modified device.
Can NKB Regovanta support IVDs in Canada?
Yes. We support Canadian IVD qualification, classification under Schedule 1 Part 2, licensing strategy, analytical and clinical performance evidence, study planning, laboratory coordination, bilingual labelling, MDSAP alignment, and post-market compliance.
Can NKB Regovanta support software and AI-enabled medical devices (SaMD)?
Yes. We support qualification, classification, software lifecycle evidence (IEC 62304), cybersecurity risk management, interoperability, clinical validation, and predetermined change control plans for machine-learning-enabled medical software.
Your Trusted Partner for Health Canada Market Access
From regulatory strategy and licensing to post-market compliance, NKB Regovanta ensures your devices reach the Canadian market with confidence and compliance.
Talk to Our Canada ExpertsAccelerate Your Health Canada MDL & MDEL Market Authorizations
Our Canadian regulatory strategists prepare audit-proof submissions, align MDSAP quality systems, and navigate pre-market reviews.